Happy to announce the first steps into NRPS/PKS engineering thanks to the work from Leonard and collaborations with the labs from Markus Kaiser and Michael Groll:
Bioengineering of syrbactin megasynthetases for immunoproteasome inhib... https://t.co/cW6McEJ4au
Happy to announce the first steps into NRPS/PKS engineering thanks to the work from Leonard and collaborations with the labs from Markus Kaiser and Michael Groll:
Bioengineering of syrbactin megasynthetases for immunoproteasome inhib... https://t.co/cW6McEJ4au
✨ Join our team ✨
@BPL_ethz is looking for 2 talented scientists!
🧑🔬 Synthetic Biology & Lab Automation: https://t.co/v691DDDl5N
🧑💻 Computer-aided Drug Design & Synthetic Biology: https://t.co/XdbAgpaI1q
🧬 Collaboration with @MyriaBio 🚀
⚡️ Apply now ⬆️
#hiring
Mit neuen Investoren startet das Basler #Biotech-#Startup@MyriaBio neu durch, um seine Hochdurchsatz-Plattform zur #Antibiotika-Entwicklung zu etablieren – und nutzt dabei unter anderem #KI … Tobias Ludwig erzählt, wo die Basler aktuell stehen: https://t.co/WUapZRfot9
The AI-driven drug discovery startup @MyriaBio, based at Tech Park Basel, has recently joined the @NVIDIAHealth Inception Program. Their platform GEMMS enables rapid creation of therapeutic agents by evaluating millions of new molecules in just one week. https://t.co/WNDDe7yywV
Big congrats to our #ETHspinoff Myria Biosciences on closing the pre-seed funding round!
> https://t.co/JifqeGVVVb
Myria is a pioneer in #drug discovery using #syntheticbiology 🧫🧪and #AI 💻
Exciting news from Myria Biosciences! We've successfully closed our pre-seed funding round, exceeding our initial target and attracting #investment from leading stars like @CreatorFund.
We're grateful for the trust and support from our investors and our community, allowing us to expand our team, kick-start our drug pipeline, and partner with Pharma leaders 🤝
Here's the magic: ✨ We engineer cells to produce & test millions of novel therapeutic molecules in a single week! This allows us to explore entirely new chemical space for highly targeted #biopharmaceuticals 🧬🦠
✨ … and our star synthetic biologist @hannah_minas for her contributions to evolution-guided engineering of trans-acyltransferase polyketide synthases.
💊 These breakthroughs propel us toward novel chemical matter for future therapies!
https://t.co/OyTVj7Oh3x
🚀 We are thrilled to celebrate two groundbreaking studies in Science. Huge congratulations to @HelgeBode_Lab and @piel_lab!
✨ Shout out to our CSO Kenan Bozhüyük, et al for developing the XUT approach, enabling tailored drug compound production…
https://t.co/WLlv6NhQKg